Endomag Outlines Commercial Ambitions Following Landmark FDA Approval
Executive Summary
Endomag is making plans to shake up the US breast cancer market with its Sentimag and Magtrace combination breast cancer system, which recently earned US FDA approval. The company recently raised $10m to scale its commercial operations.
You may also be interested in...
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
Abbott Surprises Analysts With CE Mark For Freestyle Libre 3
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.